The investment provided new specialised laboratories for the development of new dosage forms and drug delivery systems for innovative therapeutic agents, through upgrading and redevelopment of existing facilities and supported approximately 100 existing scientific, technical and related jobs at the site.
Bristol-Myers Squibb Executive Director of Biopharmaceutics R&D, Dr Peter Timmins, said:
"There are many reasons as to why Bristol-Myers Squibb has chosen to continue to significantly invest into the Wirral site, namely; the exceptional quality and availability of skilled staff, the innovation and spirit that exists among the pharmaceutical community in the region, the world class universities, the networking opportunities, the national and international connectivity, and the support received from Invest Wirral."
A state-of-the-art company, Bristol-Myers Squibb is a global leader in research and development activity with a mission of providing medicines for unmet medical needs. The 11.2 acre research plant at Moreton has a successful track record of investigating the formulation, analysis and supply of newly discovered medicines and investigating at how they can be brought to patients efficiently on a commercial scale.